Search

Displaying results 2401 - 2410 of 10000 in total
  1. Drug

    Relugolix

    go.drugbank.com/drugs/DB11853
    ApprovedInvestigational

    Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. … [A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous

    Categories: Gonadotropin Releasing Hormone Receptor Antagonists
  2. Drug

    Botulinum toxin type B

    go.drugbank.com/drugs/DB00042
    Approved

    The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps. … The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex.

  3. Drug

    Delgocitinib

    go.drugbank.com/drugs/DB16133
    ApprovedInvestigational

    [L51913] It works to reduce the inflammatory response in inflammatory skin disorders.[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508] … After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024.

  4. Drug

    Pegaspargase

    go.drugbank.com/drugs/DB00059
    ApprovedInvestigational

    The pegylation of pegaspargase allows access to the enzyme's active sites while limiting reticuloendothelial system uptake and reducing immune detection, and it also increases the half-life of L-asparaginase … [A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927]

  5. Drug

    Molybdenum

    go.drugbank.com/drugs/DB11137
    ApprovedInvestigational

    When complexed with Technetium Tc 99m, molybdenum is used as a radiopharmaceutical agent in diagonistic procedures.

    Mixtures: Venexa FE, Ribotin-E
  6. Drug

    Delamanid

    go.drugbank.com/drugs/DB11637
    ApprovedInvestigational

    It is used in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) in a combination regimen. … Spontaneous resistance to delamanid was observed during treatment, where mutation in one of the 5 F420 coenzymes responsible for bioactivation of delamanid contributes to this effect [L1407].

  7. Drug

    Elotuzumab

    go.drugbank.com/drugs/DB06317
    ApprovedInvestigational

    one to three prior therapies. … Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration.

  8. Drug

    Famotidine

    go.drugbank.com/drugs/DB00927
    ApprovedInvestigational

    Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. … [L11166] Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory

    Products: PROKSİFAM 20 MG İM/İV ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ VE ÇÖZÜCÜ, 2 ADET FLAKON + 2 ADET ÇÖZÜCÜ AMPUL
  9. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    [L54788] Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and

  10. Drug

    Pholcodine

    go.drugbank.com/drugs/DB09209
    ApprovedIllicit

    It belongs to the opioid family of compounds and it is widely used. … [A31742] Pholcodine is not prescribed in the United States where it is classed as a Schedule I drug. It is categorized as Class B drug in the UK and officially taken out of the shelves in 2008.